J
JAZZ
JAZZUnverified13 segments tracked|10 years of data|Annual (10-K)
Total Revenue
$4.1B19.0%
FY2024
Operating Segments
13Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%Xywav
Segment Shift
Xywav has grown from 0.0% to 36.2% of total revenue since FY2014, with 0.0% operating margins. Meanwhile, High Sodium AGOxybate Product Royalty Revenue is the fastest growing at +186.6% YoY.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2024
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| Xywav | $1.5B | $0 | 0.0% | 36.2% | +15.7% |
| Epidiolex Epidyolex | $972M | $0 | 0.0% | 23.9% | +15.0% |
| Rylaze Enrylaze | $411M | $0 | 0.0% | 10.1% | +0.0% |
| Zepzelca | $320M | $0 | 0.0% | 7.9% | +10.6% |
| Xyrem | $234M | $0 | 0.0% | 5.7% | -59.0% |
| High Sodium AGOxybate Product Royalty Revenue | $218M | $0 | 0.0% | 5.3% | +186.6% |
| Defitelio Defibrotide | $217M | $0 | 0.0% | 5.3% | +17.7% |
| Vyxeos | $163M | $0 | 0.0% | 4.0% | +10.2% |
| Other Royalties And Contract Revenue | $30M | $0 | 0.0% | 0.7% | +0.0% |
| Sativex | $19M | $0 | 0.0% | 0.5% | -4.0% |
| Other Products | $11M | $0 | 0.0% | 0.3% | -17.2% |
| Ziihera | $1M | $0 | 0.0% | 0.0% | +0.0% |
| Sunosi | $0 | $0 | 0.0% | 0.0% | +0.0% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free